Skip to content

T +27 (0)21 900 6277
E reception@haemalife.co.za

A 4G Riverside View Chambers
Netcare Kuils River Hospital
33 Van Riebeeck Road
Kuils River
7580


Our Team

Haematologists

Dr De Witt
Dr. Pieter de Witt
Dr Koornhof
Dr. Hannes Koornhof
Dr Cass
Dr. Michael Cass
Dr Brett
Dr. Simon Brett

Medical Officers

Dr Stockland
Dr. Liza Stockland
Dr Burton
Dr. Bianca Jade Burton

Practice Manager

Carl
Carl Toua 

Pharmacy

Zenobia
          Zenobia Bergh           
Ceceline
Cecilene Hobanie

Nursing

Sr Ina
Sr Ina Strijbis-Loubser
HWb-2
Christopher Loubser
Sr Charlie
Sr Charles Nel

Transplant Coordinators

Sr Maryna
Sr Maryna De Lange
Anne
Anne Antonie

Clinical Trials

Yzelle
Yzelle Theron
ShannonT
Shannon Gordon
Charlene
Sr Charlene Kruger
Untitled design (3)
Megan Arendse

Case Management

Sr Patrecia
Sr Patricia Harker
ShannonC
Shannon Williams
Phillida
Philida Adams
Ruedene
Ruedene Malgas

Finance

Adel
Adel Du Plessis
Nuraan
Nuraan Gordon
Michaan
Michaan Du Preez

Bookings

Janine
Janine Peters
Mishka
Mishka Williams
Chante
Chante Adams

Reception

Trizhe
Trizhé Solomon
Corin
Corrin Oktober

Support Personnel

Mariska
Mariska Gericke (Social worker)
Ingrid McDonnell (Quality control manager)
Judith
Judith Jacobus (Practise Hostess)
Untitled design (4)
Marquin Jonkers (Porter)

PATIENT TESTIMONIALS

"All the staff are super friendly and professional and there is a happy atmosphere. The illness that I have is tough to deal with and Haemalife have helped me to get back some of my old life. Thank you Haemalife Doctors and Staff"
"Ek is voorwaar bevoorreg om hier by Haemalife te kan wees. Ek wil net op hierdie stadium vir julle dankie sê wat die pad sover met ons geloop het. Elkeen van julle het 'n groot impak op my lewe gemaak. Die pad vorentoe loop ek in geloof met julle Haemalife praktyk en dankie vir elkeen se bydrae in my behandeling. Dis met 'n diepe dankbaarheid wat ek julle almal in my hart koester."

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by

CLL

Chronic Lymphocytic Leukemia (CLL) is a slow-growing cancer of B-lymphocytes, a type of white blood cell. In CLL, abnormal B-cells accumulate in the blood, bone marrow, and lymphoid tissues, often crowding out healthy cells and weakening the immune system.

Diagnosis is made through blood tests showing a high number of mature-looking lymphocytes, flow cytometry to confirm their identity, and sometimes bone marrow biopsy. Genetic testing helps predict disease course and guide treatment.

Types of CLL are classified mainly by genetic features (e.g., deletions of 17p, 13q, or mutations like TP53) and immunoglobulin heavy chain (IGHV) mutation status, which influence prognosis and therapy choice.

Treatment options depend on symptoms, disease progression, and risk factors. Many patients are initially monitored without treatment (“watch and wait”). When therapy is needed, options include targeted therapies (BTK inhibitors, BCL2 inhibitors), chemotherapy, monoclonal antibodies, and in select cases, stem cell transplantation. Supportive care focuses on managing infections and other complications.

MYELOMA

Multiple Myeloma (MM) is a cancer of plasma cells, a type of white blood cell that produces antibodies. In MM, abnormal plasma cells accumulate in the bone marrow, crowding out healthy cells and producing defective antibodies, which can cause organ damage.

Diagnosis involves blood tests (showing abnormal proteins or anemia), urine tests (detecting excess light chains), and a bone marrow biopsy. Imaging like X-rays, MRI, or PET/CT scans can detect bone lesions. Additional tests identify genetic changes that affect prognosis.

Types of Myeloma are often classified based on the type of abnormal protein produced (IgG, IgA, light-chain, etc.) and genetic features of the plasma cells. Smoldering (asymptomatic) myeloma is an early, slow-growing form.

Treatment options depend on age, health, and disease stage. Common approaches include chemotherapy, targeted therapies (like proteasome inhibitors or immunomodulators), immunotherapy (monoclonal antibodies), stem cell transplantation, and supportive care to manage bone disease, anemia, or kidney problems.

ALL

Acute Lymphoblastic Leukemia (ALL) is a fast-growing cancer of the blood and bone marrow in which immature lymphoid cells (B or T lymphocytes) multiply uncontrollably, crowding out normal blood cells and impairing immune function.

Diagnosis involves blood tests showing abnormal lymphoblasts, followed by a bone marrow biopsy. Immunophenotyping, cytogenetic, and molecular testing are used to confirm the diagnosis, classify the subtype, and assess prognosis.

Types of ALL are classified based on the lymphocyte involved (B-cell or T-cell ALL) and specific genetic abnormalities. Certain subtypes, such as Philadelphia chromosome–positive ALL, have important treatment implications.

Treatment options depend on age, risk factors, and genetic findings. Therapy typically includes multi-phase chemotherapy, targeted therapies (such as tyrosine kinase inhibitors), immunotherapy (including monoclonal antibodies or CAR T-cell therapy), and in some cases stem cell transplantation. Supportive care is essential throughout treatment.

AML

Acute Myeloid Leukemia (AML) is a fast-growing cancer of the blood and bone marrow in which abnormal myeloid cells multiply and crowd out normal blood cells, leading to anemia, infections, and bleeding.

Diagnosis is made through blood tests showing abnormal cells, followed by a bone marrow biopsy. Additional tests such as cytogenetic, molecular, and immunophenotyping studies help confirm AML and guide treatment.

Types of AML are classified based on cell appearance and genetic changes. Major systems include the WHO and FAB classifications. Subtypes are defined by specific chromosome or gene abnormalities, such as acute promyelocytic leukemia (APL), which requires specialized therapy.

Treatment options depend on patient age, health, and AML subtype. They may include intensive chemotherapy, targeted therapies (such as FLT3 or IDH inhibitors), immunotherapy, and stem cell (bone marrow) transplantation. Supportive care, including antibiotics and blood transfusions, is also essential.